Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02507544 · ClinicalTrials.gov registry record · Phase 1
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
A Phase 1 study of Advanced Cancer and Carcinoma, sponsored by TaiRx.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT02507544: Completed Phase 1 study of Advanced Cancer and Carcinoma, sponsored by TaiRx.
NCT02507544 is a Phase 1 study of Advanced Cancer and Carcinoma that has completed, run by TaiRx. The registered enrollment target is 36 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02507544, a Phase 1 study of Advanced Cancer and Carcinoma, has completed, sponsored by TaiRx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines. The objectives of this study are to determine the safety profile of TRX-818 including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) and determine the recommended dose and regimen(s) to initiate Phase 2.
Primary Outcome
Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0.
Conditions Studied
Interventions
- DRUG TRX-818 capsules
Study Locations (2)
Michigan
- START Midwest - Grand Rapids
Texas
- South Texas Accelerated Research Therapeutics, LLC (START) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-05-20 |
| Phase | Phase 1 |
What the finished NCT02507544 record still lists
NCT02507544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which TRX-818 capsules is the first listed.
NCT02507544 reports a single indexed study location in Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT02507544 about?
NCT02507544 is a clinical study titled "A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer". TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines. The objectives of this study are to determine the safety profile of TRX-818 including identification of dos...
What is the current status of trial NCT02507544?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2015-09. Estimated completion is 2019-05-20.
What conditions does trial NCT02507544 study?
This clinical trial studies the following conditions: Advanced Cancer, Carcinoma.
What interventions are being tested in trial NCT02507544?
The interventions under investigation include: TRX-818 capsules (DRUG).
Who is sponsoring clinical trial NCT02507544?
This trial is sponsored by TaiRx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02507544 being conducted?
This trial has 2 study locations across Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02507544's enrollment target sits among peer trials
36 95th of 122 higher than 27 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia